Mihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award

Friday, December 13, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will present its inaugural Trailblazer Award to Mihael H. Polymeropoulos, MD, Vanda's President and CEO. The honor has been given to acknowledge Dr. Polymeropoulos for his leadership and unwavering commitment to modernize drug testing and improve human safety.

"I am honored to receive this award from the Physicians Committee for Responsible Medicine and to be recognized for our efforts to abandon unscientific, low-resolution animal testing and adopt modern, human-based scientific methods to advance human drug safety," said Dr. Polymeropoulos.

For more information on the Trailblazer Award announcement visit:  https://www.pcrm.org/news/news-releases/vanda-pharmaceuticals-president-receives-award-work-prevent-fda-dog-tests

ABOUT VANDA PHARMACEUTICALS INC.: Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Corporate Contact: AJ Jones II Chief Corporate Affairs and Communications Officer Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

Elizabeth Van Every Head of Corporate Affairs Vanda Pharmaceuticals Inc. 202-734-3400 pr@vandapharma.com

Cision View original content:http://www.prnewswire.com/news-releases/mihael-h-polymeropoulos-md-president-and-ceo-of-vanda-pharmaceuticals-inc-to-receive-the-physicians-committee-for-responsible-medicine-trailblazer-award-300974376.html

SOURCE Vanda Pharmaceuticals Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Premium Membership Benefits

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store